This transcript has been edited for clarity.
Dear colleagues, I am Christoph Diener, from the medical faculty of the University Duisburg-Essen in Germany, and I want to report what happened in the first 6 weeks of 2022 in neurology, focused on multiple sclerosis and stroke.
Let me start with the spectacular publication in Science on the possible relationship between Epstein-Barr virus infections and multiple sclerosis. This paper is based on 10 million people in the American Army who were followed from 1993 to 2013. In this population, 925 people developed multiple sclerosis; serum samples were available from 801 people and 800 had positive titers against Epstein-Barr virus. This was much higher than in the control population. For cytomegalovirus infections, there was no difference.
When they looked at the conversion rate for Epstein-Barr virus in serum, this was the case in 97% of the patients with multiple sclerosis, but only in 57% in the control group. These data would suggest that there is an association between Epstein-Barr virus infection and multiple sclerosis, but this does not mean this is a causal relationship. There was a large amount of public press coverage of this study. The conclusion was that possibly a vaccination against Epstein-Barr virus would prevent multiple sclerosis, but unfortunately, this vaccination is not yet available.
COMMENTARY
Recent Findings in Neurology: Multiple Sclerosis and Stroke
Hans-Christoph Diener, MD, PhD
DisclosuresApril 06, 2022
This transcript has been edited for clarity.
Dear colleagues, I am Christoph Diener, from the medical faculty of the University Duisburg-Essen in Germany, and I want to report what happened in the first 6 weeks of 2022 in neurology, focused on multiple sclerosis and stroke.
Let me start with the spectacular publication in Science on the possible relationship between Epstein-Barr virus infections and multiple sclerosis. This paper is based on 10 million people in the American Army who were followed from 1993 to 2013. In this population, 925 people developed multiple sclerosis; serum samples were available from 801 people and 800 had positive titers against Epstein-Barr virus. This was much higher than in the control population. For cytomegalovirus infections, there was no difference.
When they looked at the conversion rate for Epstein-Barr virus in serum, this was the case in 97% of the patients with multiple sclerosis, but only in 57% in the control group. These data would suggest that there is an association between Epstein-Barr virus infection and multiple sclerosis, but this does not mean this is a causal relationship. There was a large amount of public press coverage of this study. The conclusion was that possibly a vaccination against Epstein-Barr virus would prevent multiple sclerosis, but unfortunately, this vaccination is not yet available.
Medscape Neurology © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Hans-Christoph Diener. Recent Findings in Neurology: Multiple Sclerosis and Stroke - Medscape - Apr 06, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Hans-Christoph Diener, MD, PhD
Professor, Department of Neurology, Stroke Center-Headache Center, University Duisburg-Essen, Essen, Germany
Disclosure: Hans-Christoph Diener, MD, PhD, has disclosed the following relevant financial relationships:
Received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott; Addex Pharma; Alder; Allergan; Almirall; Amgen; Autonomic Technology; AstraZeneca; Bayer Vital; Berlin Chemie; Bristol-Myers Squibb; Boehringer Ingelheim; Chordate; CoAxia; Corimmun; Covidien; Coherex; CoLucid; Daiichi-Sankyo; D-Pharml Electrocore; Fresenius; GlaxoSmithKline; Grunenthal; Janssen-Cilag; Labrys Biologics Lilly; La Roche; 3M Medica; MSD; Medtronic; Menarini; MindFrame; Minster; Neuroscore; Neurobiological Technologies; Novartis; Novo-Nordisk; Johnson & Johnson; Knoll; Paion; Parke-Davis; Pierre Fabre; Pfizer Inc; Schaper and Brummer; sanofi-aventis; Schering-Plough; Servier; Solvay; Syngis; St. Jude; Talecris; Thrombogenics; WebMD Global; Weber and Weber; Wyeth; Yamanouchi
Received financial support for research projects from: Allergan; Almirall; Astra/Zeneca; Bayer; Boehringer Ingelheim; Electrocore; GlaxoSmithKline; Janssen-Cilag; Lundbeck; MSD; Novartis; Pfizer; sanofi-aventis; Syngis; Talecris
Within the past year Dr Diener served as editor of Aktuelle Neurologie, Arzneimitteltherapie, Kopfschmerznews, Stroke News, and the Treatment Guidelines of the German Neurological Society; as co-editor of Cephalalgia, and on the editorial board of Lancet Neurology, Stroke, European Neurology, and Cerebrovascular Disorders.
The Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), European Union, National Institutes of Health, Bertelsmann Foundation, and Heinz-Nixdorf Foundation.
Dr Diener has no ownership interest and does not own stocks in any pharmaceutical company.